Our discovery that resistance to sunitinib in RCC cells is associated with hyperactivation of CDK4-RB suggests CDK4 as a potential target in future treatment of mRCC patients who have developed resistance to sunitinib. This evidence concerns the gene CDK4 and renal cell carcinoma.